The DOI matches its Crossref record; 42 of the 44 references it cites were found in a registry or an index.
IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype
Open accessAbstract
Both genome-wide genetic and epigenetic alterations are fundamentally important for the development of cancers, but the interdependence of these aberrations is poorly understood. Glioblastomas and other cancers with the CpG island methylator phenotype (CIMP) constitute a subset of tumours with extensive epigenomic aberrations and a distinct biology. Glioma CIMP (G-CIMP) is a powerful determinant of tumour pathogenicity, but the molecular basis of G-CIMP remains unresolved. Here we show that mutation of a single gene, isocitrate dehydrogenase 1 (IDH1), establishes G-CIMP by remodelling the methylome. This remodelling results in reorganization of the methylome and transcriptome. Examination of the epigenome of a large set of intermediate-grade gliomas demonstrates a distinct G-CIMP phenotype that is highly dependent on the presence of IDH mutation. Introduction of mutant IDH1 into primary human astrocytes alters specific histone marks, induces extensive DNA hypermethylation, and reshapes the methylome in a fashion that mirrors the changes observed in G-CIMP-positive lower-grade gliomas. Furthermore, the epigenomic alterations resulting from mutant IDH1 activate key gene expression programs, characterize G-CIMP-positive proneural glioblastomas but not other glioblastomas, and are predictive of improved survival. Our findings demonstrate that IDH mutation is the molecular basis of CIMP in gliomas, provide a framework for understanding oncogenesis in these gliomas, and highlight the interplay between genomic and epigenomic changes in human cancers.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“IDH mutant gliomas thus manifest a CpG island methylator phenotype (G-CIMP)10,11, though the functional significance of this altered epigenetic state remains unclear.”
From Insulator dysfunction and oncogene activation in IDH mutant gliomas (2016) · cites this paper as [11]
In the citing paper
“As a result, D-2HG accumulation in cancer cells expressing mutant IDH results in hypermethylation of histones and CpG islands in DNA (Figueroa et al., 2010; Lu et al., 2012; Turcan et al., 2012).”
From Targeting Metabolism for Cancer Therapy (2017) · cites this paper as Turcan et al., 2012
In the citing paper
“Specifically, owing to the interference with TET family proteins, the mutation causes the CpG island methylator phenotype116,123.”
From Transcription factors as readers and effectors of DNA methylation (2016) · cites this paper as [123]
In the citing paper
“Indeed, IDH-driven gliomas, leukemias and chondrosarcomas display a prominent CpG island hypermethylation, reminiscent of the hypermethylator phenotype seen in SDH- and FH-deficient cancers (Figueroa et al., 2010; Lu et al., 2013; Turcan et al., 2012).”
From The emerging hallmarks of cancer metabolism (2016) · cites this paper as Turcan et al., 2012
In the citing paper
“In the cancer setting, 2-HG has been shown to influence a number of biological processes, including cell differentiation, DNA methylation, and histone methylation (79–82), leading to its classification as an oncometabolite.”
From Fueling Immunity: Insights into Metabolism and Lymphocyte Function (2013) · cites this paper as [82]
In the citing paper
“Like TH17 cells, CD8+ T cells are highly dependent on the activation of HIF-1α and glycolysis, which is responsible for mediating trafficking into hypoxic tumour environments and inflamed tissue147,148.”
From Coupling Krebs cycle metabolites to signalling in immunity and cancer (2018) · cites this paper as [147]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Subramanian, A., Tamayo, P., Mootha, V. K., Mukherjee, S., Ebert, B. L., Gillette, M. A., Paulovich, A., Pomeroy, S. L., Golub, T. R., Lander, E. S., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0506580102 · Cited by 53,625
Comprehensive genomic characterization defines human glioblastoma genes and core pathways
The Cancer Genome Atlas Research Network (2008) · Nature · doi:10.1038/nature07385 · Cited by 7,735
Verhaak, R. G. W., Hoadley, K. A., Purdom, E., Wang, V., Qi, Y., Wilkerson, M. D., Miller, C. R., Ding, L., Golub, T., Mesirov, J. P., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2009.12.020 · Cited by 7,575
MGMT Gene Silencing and Benefit from Temozolomide in Glioblastoma
Hegi, M. E., Diserens, A.-C., Gorlia, T., Hamou, M.-F., de Tribolet, N., Weller, M., Kros, J. M., Hainfellner, J. A., Mason, W., Mariani, L., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa043331 · Cited by 7,405
An Integrated Genomic Analysis of Human Glioblastoma Multiforme
Parsons, D. W., Jones, S., Zhang, X., Lin, J. C.-H., Leary, R. J., Angenendt, P., Mankoo, P., Carter, H., Siu, I.-M., Gallia, G. L., et al. (2008) · Science · doi:10.1126/science.1164382 · Cited by 5,857
IDH1 and IDH2 Mutations in Gliomas
Yan, H., Parsons, D. W., Jin, G., McLendon, R., Rasheed, B. A., Yuan, W., Kos, I., Batinic-Haberle, I., Jones, S., Riggins, G. J., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0808710 · Cited by 5,847
Jones, P. A., & Baylin, S. B. (2007) · Cell · doi:10.1016/j.cell.2007.01.029 · Cited by 4,515
Cancer-associated IDH1 mutations produce 2-hydroxyglutarate
Dang, L., White, D. W., Gross, S., Bennett, B. D., Bittinger, M. A., Driggers, E. M., Fantin, V. R., Jang, H. G., Jin, S., Keenan, M. C., et al. (2009) · Nature · doi:10.1038/nature08617 · Cited by 4,154
Self-citationConsed: a graphical tool for sequence finishing.Preprint
Gordon, D., Abajian, C., & Green, P. (1998) · Genome Research · doi:10.1101/gr.8.3.195 · Cited by 3,706
CNS stem cells express a new class of intermediate filament protein
Lendahl, U., Zimmerman, L. B., & McKay, R. D. G. (1990) · Cell · doi:10.1016/0092-8674(90)90662-x · Cited by 3,164
Cited by
Sorted by citations
Items 601–700 of 1,002
Management of glioblastoma in elderly patients
Young, J. S., Chmura, S. J., Wainwright, D. A., Yamini, B., Peters, K. B., & Lukas, R. V. (2017) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2017.07.048 · Cited by 50
Transcriptomic analysis of CIC and ATXN1L reveal a functional relationship exploited by cancer
Wong, D., Lounsbury, K., Lum, A. M., Song, J., Chan, S. Y., Leblanc, V., Chittaranjan, S., Marra, M. A., & Yip, S. S. F. (2018) · Oncogene · doi:10.1038/s41388-018-0427-5 · Cited by 49
Noreen, F., Küng, T., Tornillo, L., Parker, H. R., Silva, M. G., Weis, S., Marra, G., Rad, R., Truninger, K., & Schär, P. (2019) · Clinical Epigenetics · doi:10.1186/s13148-019-0791-1 · Cited by 49
Directional integration and pathway enrichment analysis for multi-omics data
Slobodyanyuk, M., Bahcheli, A. T., Klein, Z. P., Bayati, M., Strug, L. J., & Reimand, J. (2024) · Nature Communications · doi:10.1038/s41467-024-49986-4 · Cited by 52
Novel Therapeutic Targets of Tumor Metabolism
Kishton, R. J., & Rathmell, J. C. (2015) · The Cancer Journal · doi:10.1097/ppo.0000000000000099 · Cited by 48
A Brain Penetrant Mutant IDH1 Inhibitor Provides In Vivo Survival Benefit
Kopinja, J. E., Sevilla, R. S., Levitan, D. J., Dai, D. L., Vanko, A., Spooner, E., Ware, C., Forget, R., Hu, K., Kral, A. M., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-14065-w · Cited by 49
Verduin, M., Compter, I., Steijvers, D., Postma, A. A., Eekers, D. B. P., Anten, M. H. M. E., Ackermans, L. P. C. M., ter Laan, M., Leijenaar, R. T. H., van de Weijer, T., et al. (2018) · Disease Markers · doi:10.1155/2018/2908609 · Cited by 50
Uckermann, O., Yao, W., Juratli, T. A., Galli, R., Leipnitz, E., Meinhardt, M., Koch, E., Schackert, G., Steiner, G. R., & Kirsch, M. (2018) · Journal of Neuro-Oncology · doi:10.1007/s11060-018-2883-8 · Cited by 50
Rates and Patterns of Clonal Oncogenic Mutations in the Normal Human Brain
Ganz, J., Maury, E. A., Becerra, B., Bizzotto, S., Doan, R. N., Kenny, C. J., Shin, T., Kim, J., Zhou, Z., Ligon, K. L., et al. (2022) · Cancer Discovery · doi:10.1158/2159-8290.cd-21-0245 · Cited by 48
Metabolic Regulation of Epigenetic Modifications and Cell Differentiation in Cancer
Saggese, P., Sellitto, A., Martinez, C. A., Giurato, G., Nassa, G., Rizzo, F. M., Tarallo, R., & Scafoglio, C. (2020) · Cancers · doi:10.3390/cancers12123788 · Cited by 46
Gunn, K., Myllykoski, M., Cao, J. Z., Ahmed, M., Huang, B., Rouaisnel, B., Diplas, B. H., Levitt, M. M., Looper, R., Doench, J. G., et al. (2023) · Cancer Discovery · doi:10.1158/2159-8290.cd-22-0825 · Cited by 57
Spratt, D. E., Folkert, M. R., Zumsteg, Z. S., Chan, T. A.-T., Beal, K. P., Gutin, P. H., Pentsova, E. I., & Yamada, Y. J. (2013) · Journal of Neuro-Oncology · doi:10.1007/s11060-013-1302-4 · Cited by 48
Self-citationWang, J., Dong, D.-F., Wang, M., & Gao, K. (2014) · Asian Pacific Journal of Cancer Prevention · doi:10.7314/apjcp.2014.15.1.427 · Cited by 48
FOXOs support the metabolic requirements of normal and tumor cells by promoting IDH1 expression
Charitou, P., Colman, M. J. R., Gerrits, J., van Triest, M. H., Koerkamp, M. J. A. G., Hornsveld, M., Holstege, F. C. P., Verhoeven‐Duif, N. M., & Burgering, B. M. T. (2015) · EMBO Reports · doi:10.15252/embr.201439096 · Cited by 47
Precision medicine driven by cancer systems biology
Filipp, F. V. (2017) · Cancer and Metastasis Reviews · doi:10.1007/s10555-017-9662-4 · Cited by 52
Oncometabolites in cancer aggressiveness and tumour repopulation
Dando, I., Pozza, E. D., Ambrosini, G., Torrens‐Mas, M., Butera, G., Mullappilly, N., Pacchiana, R., Palmieri, M., & Donadelli, M. (2019) · Biological reviews/Biological reviews of the Cambridge Philosophical Society · doi:10.1111/brv.12513 · Cited by 49
Reprogramming acute myeloid leukemia into sensitivity for retinoic-acid-driven differentiation
van Gils, N., Verhagen, H. J. M. P., & Smit, L. (2017) · Experimental Hematology · doi:10.1016/j.exphem.2017.04.007 · Cited by 49
Mur, P., de Lope, Á. R., Diaz-Crespo, F. J., Hernández‐Iglesias, T., Ribalta, T., Fiaño, C., García, J. F., REY, J. A., Mollejo, M., & Meléndez, B. (2015) · Journal of Neuro-Oncology · doi:10.1007/s11060-015-1738-9 · Cited by 48
Emerging technologies for studying DNA methylation for the molecular diagnosis of cancer
Marzese, D. M., & Hoon, D. S. �. (2015) · Expert Review of Molecular Diagnostics · doi:10.1586/14737159.2015.1027194 · Cited by 47
Clinical Relevance of Prognostic and Predictive Molecular Markers in Gliomas
Siegal, T. (2015) · Advances and technical standards in neurosurgery · doi:10.1007/978-3-319-21359-0_4 · Cited by 50
The Effect of Molecular Diagnostics on the Treatment of Glioma
Bush, N. A. O., & Butowski, N. A. (2017) · Current Oncology Reports · doi:10.1007/s11912-017-0585-6 · Cited by 47
Yang, Z., Xu, F., Wang, H., Teschendorff, A. E., Xie, F., & He, Y. (2021) · EBioMedicine · doi:10.1016/j.ebiom.2021.103399 · Cited by 50
Treatment of IDH-mutant glioma in the INDIGO era
Lin, M. D., Tsai, A. C.-Y., Abdullah, K. G., McBrayer, S. K., & Shi, D. D. (2024) · npj Precision Oncology · doi:10.1038/s41698-024-00646-2 · Cited by 51
Glial Progenitors as Targets for Transformation in Glioma
Ilkhanizadeh, S., Lau, J., Huang, M., Foster, D. J., Wong, R. A., Frantz, A., Wang, S., Weiss, W. A., & Persson, A. I. (2014) · Advances in cancer research · doi:10.1016/b978-0-12-800249-0.00001-9 · Cited by 47
Rakheja, D., Medeiros, L. J., Bevan, S., & Chen, W. (2013) · Frontiers in Oncology · doi:10.3389/fonc.2013.00169 · Cited by 47
IDH1/IDH2but NotTP53Mutations Predict Prognosis in Bulgarian Glioblastoma Patients
Stancheva, G. S., Goranova, T., Laleva, M., Kamenova, M. A., Mitkova, A. V., Velinov, N., Poptodorov, G., Mitev, V., Kaneva, R. P., & Gabrovsky, N. (2014) · BioMed Research International · doi:10.1155/2014/654727 · Cited by 46
IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype
Uhm, J. H. (2012) · Yearbook of Neurology and Neurosurgery · doi:10.1016/j.yneu.2012.05.008 · Cited by 46
Millward, C. P., Brodbelt, A. R., Haylock, B. J., Zakaria, R., Baborie, A., Crooks, D. A., Husband, D. J., Shenoy, A., Wong, H. H., & Jenkinson, M. D. (2016) · Acta Neurochirurgica · doi:10.1007/s00701-016-2928-8 · Cited by 46
Glioblastoma Treatment in the Elderly
Okada, M., Miyake, K., & Tamiya, T. (2017) · Neurologia medico-chirurgica · doi:10.2176/nmc.ra.2017-0009 · Cited by 46
Waitkus, M. S., Pirozzi, C. J., Moure, C. J., Diplas, B. H., Hansen, L. J., Carpenter, A. B., Yang, R. R., Wang, Z., Ingram, B. O., Karoly, E. D., et al. (2017) · Cancer Research · doi:10.1158/0008-5472.can-17-1352 · Cited by 48
Madala, H. R., Punganuru, S. R., Arutla, V., Misra, S., Thomas, T., & Srivenugopal, K. S. (2018) · Cancers · doi:10.3390/cancers10020049 · Cited by 46
Viswanath, P., Radoul, M., Izquierdo-García, J. L., Luchman, H. A., Cairncross, J. G., Pieper, R. O., Phillips, J. J., & Ronen, S. M. (2018) · Cancer & Metabolism · doi:10.1186/s40170-018-0178-3 · Cited by 48
Yan, B., Liu, S., Shi, Y., Liu, N., Chen, L., Wang, X., Xiao, D., Liu, X., Mao, C., Jiang, Y., et al. (2018) · Cell Death and Disease · doi:10.1038/s41419-018-0542-9 · Cited by 47
Bond, C., & Whitehall, V. (2018) · Gastroenterology Research and Practice · doi:10.1155/2018/9250757 · Cited by 48
Pheochromocytomas and Paragangliomas: From Genetic Diversity to Targeted Therapies
Pang, Y. K., Liu, Y., Pacák, K., & Yang, C. (2019) · Cancers · doi:10.3390/cancers11040436 · Cited by 48
Post-translational modifications on mitochondrial metabolic enzymes in cancer
Peng, Y., Liu, H., Liu, J., & Long, J. (2021) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2021.12.264 · Cited by 49
Glioblastoma microenvironment—from biology to therapyPreprint
Read, R. D., Tapp, Z. M., Rajappa, P., & Hambardzumyan, D. (2024) · Genes & Development · doi:10.1101/gad.351427.123 · Cited by 51
Dettling, S., Stamova, S., Warta, R., Schnölzer, M., Rapp, C., Rathinasamy, A., Reuß, D., Pocha, K., Roesch, S., Jungk, C., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-1839 · Cited by 45
Murugan, A. K., & Alzahrani, A. (2022) · British Journal of Biomedical Science · doi:10.3389/bjbs.2021.10208 · Cited by 45
Epigenetic enzyme mutations as mediators of anti-cancer drug resistance
Chen, S., Zhao, Y., Liu, S., Zhang, J., Assaraf, Y. G., Cui, W., & Wang, L. (2022) · Drug Resistance Updates · doi:10.1016/j.drup.2022.100821 · Cited by 47
Metabolite regulation of epigenetics in cancer
Wang, P., Chen, L., Xiong, Y., & Ye, D. (2024) · Cell Reports · doi:10.1016/j.celrep.2024.114815 · Cited by 50
Mutant IDH1 inhibits PI3K/Akt signaling in human glioma
Birner, P., Pusch, S., Christov, C., Mihaylova, S., Toumangelova‐Uzeir, K., Natchev, S., SCHOPPMANN, S. F., Tchorbanov, A. I., Streubel, B., Tuettenberg, J., et al. (2014) · Cancer · doi:10.1002/cncr.28732 · Cited by 46
Prognostic and Predictive Biomarkers in Adult and Pediatric Gliomas: Toward Personalized Treatment
Haynes, H. R., Camelo-Piragua, S. I., & Kurian, K. M. (2014) · Frontiers in Oncology · doi:10.3389/fonc.2014.00047 · Cited by 45
Elevation of Urinary 2-Hydroxyglutarate in IDH-Mutant Glioma
Fathi, A. T., Nahed, B. V., Wander, S. A., Iafrate, A. J., Borger, D. R., Hu, R., Thabet, A., Cahill, D. P., Perry, A. M., Joseph, C. P., et al. (2016) · The Oncologist · doi:10.1634/theoncologist.2015-0342 · Cited by 46
Hatae, R., Hata, N., Yoshimoto, K., Kuga, D., Akagi, Y., Murata, H., Suzuki, S. O., Mizoguchi, M., & Iihara, K. (2016) · PLoS ONE · doi:10.1371/journal.pone.0160489 · Cited by 45
Integrative modelling of tumour DNA methylation quantifies the contribution of metabolism
Mehrmohamadi, M., Mentch, L., Clark, A. G., & Locasale, J. W. (2016) · Nature Communications · doi:10.1038/ncomms13666 · Cited by 49
Badur, M. G., & Metallo, C. M. (2017) · Metabolic Engineering · doi:10.1016/j.ymben.2017.11.013 · Cited by 44
Unruh, D. J., Mirkov, S., Wray, B. D., Drumm, M. R., Lamano, J. B., Li, Y. D., Haider, Q. F., Javier, R., McCortney, K., Saratsis, A. M., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-1222 · Cited by 44
Significance of TERT and ATRX mutations in glioma
Liu, J., Zhang, X., Xiao-ling, Y. A. N., Sun, M., Fan, Y., & Huang, Y. (2018) · Oncology Letters · doi:10.3892/ol.2018.9634 · Cited by 50
Biliary Tract Cancers: Molecular Heterogeneity and New Treatment Options
Personeni, N., Lleò, A., Pressiani, T., Colapietro, F., Openshaw, M. R., Stavraka, C., Pouptsis, A., Pinato, D. J., & Rimassa, L. (2020) · Cancers · doi:10.3390/cancers12113370 · Cited by 45
Bunse, L., Rupp, A.-K., Poschke, I. C., Bunse, T., Lindner, K. A. M., Wick, A., Blobner, J., Misch, M., Tabatabai, G., Glas, M., et al. (2022) · Neurological Research and Practice · doi:10.1186/s42466-022-00184-x · Cited by 45
Characterization of systemic immunosuppression by IDH mutant glioma small extracellular vesicles
Ludwig, N., Rao, A., Sandlesh, P., Yerneni, S. S., Swain, A. D., Bullock, K. M., Hansen, K. M., Zhang, X., Jaman, E., Allen, J., et al. (2021) · Neuro-Oncology · doi:10.1093/neuonc/noab153 · Cited by 46
Classification and Diagnosis of Adult Glioma: A Scoping Review
Byun, Y. H., & Park, C. (2022) · Brain & Neurorehabilitation · doi:10.12786/bn.2022.15.e23 · Cited by 48
Systemic and local immunosuppression in glioblastoma and its prognostic significance
Stepanenko, A. A., Sosnovtseva, A. O., Valikhov, M. P., Chernysheva, A. A., Abramova, O. V., Ka, P., & Chekhonin, V. P. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1326753 · Cited by 48
Klink, B., Miletić, H., Stieber, D., Huszthy, P. C., Valenzuela, J. A. C., Balß, J., Wang, J., Schubert, M., Sakariassen, P. Ø., Sundstrøm, T., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0059773 · Cited by 44
Mur, P., Mollejo, M., Hernández‐Iglesias, T., de Lope, Á. R., Castresana, J. S., García, J. F., Fiaño, C., Ribalta, T., REY, J. A., & Meléndez, B. (2015) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/nen.0000000000000167 · Cited by 45
Molecular and Epigenetic Mechanisms of MLL in Human Leukemogenesis
Ballabio, E., & Milne, T. A. (2012) · Cancers · doi:10.3390/cancers4030904 · Cited by 46
Baysan, M. S., Woolard, K., Bozdag, S., Riddick, G., Kotliarova, S. E., Cam, M. C., Belova, G. I., Ahn, S. J., Zhang, W., Song, H., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0094045 · Cited by 46
Gliomas Genomics and Epigenomics: Arriving at the Start and Knowing It for the First Time
Filbin, M. G., & Suvà, M. L. (2016) · Annual Review of Pathology Mechanisms of Disease · doi:10.1146/annurev-pathol-012615-044208 · Cited by 46
Overview of DNA methylation in adult diffuse gliomas
Aoki, K., & Natsume, A. (2019) · Brain Tumor Pathology · doi:10.1007/s10014-019-00339-w · Cited by 45
LncRNA FOXD1‐AS1 acts as a potential oncogenic biomarker in glioma
Gao, Y., Liu, J., Mao, X., He, Z.-W., Zhu, T., Wang, Z., Li, X., Yin, J., Zhang, W., Zhou, H., et al. (2019) · CNS Neuroscience & Therapeutics · doi:10.1111/cns.13152 · Cited by 44
STATegra: Multi-Omics Data Integration – A Conceptual Scheme With a Bioinformatics Pipeline
Planell, N., Lagani, V., Sebastián-León, P., van der Kloet, F. M., Ewing, E., Karathanasis, N., Urdangarin, A., Arozarena, I., Jagodic, M., Tsamardinos, I., et al. (2021) · Frontiers in Genetics · doi:10.3389/fgene.2021.620453 · Cited by 46
Epigenetics of Most Aggressive Solid Tumors: Pathways, Targets and Treatments
Martínez‐Useros, J., Martin-Galan, M., Florez-Cespedes, M., & García‐Foncillas, J. (2021) · Cancers · doi:10.3390/cancers13133209 · Cited by 46
PRMT1 driven PTX3 regulates ferritinophagy in glioma
Lathoria, K., Gowda, P., Umdor, S. B., Patrick, S., Suri, V. S., & Sen, E. (2023) · Autophagy · doi:10.1080/15548627.2023.2165757 · Cited by 42
Shen, Y., Thng, D. K. H., Wong, A. L. A., & Toh, T. B. (2024) · Experimental Hematology and Oncology · doi:10.1186/s40164-024-00512-8 · Cited by 47
IDH mutations in liver cell plasticity and biliary cancer
Saha, S. K., Parachoniak, C. A., & Bardeesy, N. M. (2014) · Cell Cycle · doi:10.4161/15384101.2014.965054 · Cited by 46
Alberghina, L., Gaglio, D., Gelfi, C., Moresco, R. M., Mauri, G., Bertolazzi, P., Messa, C., Gilardi, M. C., Chiaradonna, F., & Vanoni, M. (2012) · Frontiers in Physiology · doi:10.3389/fphys.2012.00362 · Cited by 45
Characteristics of gliomas in patients with somatic IDH mosaicism
Bonnet, C., Thomas, L., Psimaras, D., Bielle, F., Vauléon, É., Loiseau, H., Cartalat‐Carel, S., Meyronet, D., Dehais, C., Honnorat, J., et al. (2016) · Acta Neuropathologica Communications · doi:10.1186/s40478-016-0302-y · Cited by 43
Joberty, G., Böesche, M., Brown, J. A., Eberhard, D., Garton, N. S., Humphreys, P. G., Mathieson, T., Muelbaier, M., Ramsden, N. G., Reader, V., et al. (2016) · ACS Chemical Biology · doi:10.1021/acschembio.6b00080 · Cited by 44
Molecular markers of paragangliomas/pheochromocytomas
Zhikrivetskaya, S. O., Snezhkina, A. V., Zaretsky, A. R., Alekseev, B. Y., Pokrovsky, A. V., Golovyuk, A. L., Melnikova, N. V., Stepanov, O. A., Kalinin, D. V., Moskalev, A., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.15201 · Cited by 45
Metabolism and Transcription in Cancer: Merging Two Classic Tales
Martín-Martín, N., Carracedo, A., & Torrano, V. (2018) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2017.00119 · Cited by 43
Zhou, Z., Ibekwe, E., & Chornenkyy, Y. (2018) · Antioxidants · doi:10.3390/antiox7010016 · Cited by 44
Abe, H., Natsumeda, M., Kanemaru, Y., Watanabe, J., Tsukamoto, Y., Okada, M., Yoshimura, J., Oishi, M., & Fujii, Y. (2018) · Neurologia medico-chirurgica · doi:10.2176/nmc.ra.2018-0044 · Cited by 43
Johnson, A., Laterra, J., & López-Bertoni, H. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.995498 · Cited by 45
Evolving cell states and oncogenic drivers during the progression of IDH-mutant gliomas
Wu, J., Castro, L. N. G., Battaglia, S., Farran, C. A. E., D’Antonio, J. P., Miller, T. E., Suvà, M. L., & Bernstein, B. (2024) · Nature Cancer · doi:10.1038/s43018-024-00865-3 · Cited by 48
Jones, S. D., Ahmet, J., Ayton, K., Ball, M. D., Cockerill, M. J., Fairweather, E. E., Hamilton, N. S., Harper, P., Hitchin, J. R., Jordan, A. M., et al. (2016) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6b01320 · Cited by 42
Mutant IDH1 Disrupts the Mouse Subventricular Zone and Alters Brain Tumor Progression
Pirozzi, C. J., Carpenter, A. B., Waitkus, M. S., Wang, C. Y., Zhu, H., Hansen, L. J., Chen, L. H., Greer, P. K., Feng, J., Wang, Y., et al. (2017) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-16-0485 · Cited by 42
Gowda, P., Patrick, S., Singh, A., Sheikh, T., & Sen, E. (2018) · Molecular and Cellular Biology · doi:10.1128/mcb.00001-18 · Cited by 43
Sun, X., & John, J. C. S. (2018) · Epigenetics & Chromatin · doi:10.1186/s13072-018-0223-z · Cited by 42
Impact of CDKN2A/B Homozygous Deletion on the Prognosis and Biology of IDH-Mutant Glioma
Huang, L. E. (2022) · Biomedicines · doi:10.3390/biomedicines10020246 · Cited by 43
IDH Mutations in Glioma: Molecular, Cellular, Diagnostic, and Clinical Implications
Choate, K. A., Pratt, E. P. S., Jennings, M. J., Winn, R. J., & Mann, P. B. (2024) · Biology · doi:10.3390/biology13110885 · Cited by 49
Genetic similarity between cancers and comorbid Mendelian diseases identifies candidate driver genes
Melamed, R., Emmett, K., Madubata, C. J., Rzhetsky, A., & Rabadán, R. (2015) · Nature Communications · doi:10.1038/ncomms8033 · Cited by 43
Cancer subtypes classification using long non-coding RNA
Flippot, R., Malouf, G. G., Su, X., Mouawad, R., Spano, J., & Khayat, D. (2016) · Oncotarget · doi:10.18632/oncotarget.10213 · Cited by 42
Grade II and III Oligodendroglioma and Astrocytoma
van den Bent, M. J., & Chang, S. M. (2018) · Neurologic Clinics · doi:10.1016/j.ncl.2018.04.005 · Cited by 44
Location-Dependent Patient Outcome and Recurrence Patterns in IDH1-Wildtype Glioblastoma
Jungk, C., Warta, R., Möck, A., Friauf, S., Hug, B., Capper, D., Abdollahi, A., Debus, J., Bendszus, M., von Deimling, A., et al. (2019) · Cancers · doi:10.3390/cancers11010122 · Cited by 41
A Multi-Cohort and Multi-Omics Meta-Analysis Framework to Identify Network-Based Gene Signatures
Shafi, A., Nguyen, T., Peyvandipour, A., Nguyen, H., & Drăghici, S. (2019) · Frontiers in Genetics · doi:10.3389/fgene.2019.00159 · Cited by 43
IDH Inhibitors and Beyond: The Cornerstone of Targeted Glioma Treatment
Gatto, L., Franceschi, E., Tosoni, A., Nunno, V. D., Maggio, I., Lodi, R., & Brandes, A. A. (2021) · Molecular Diagnosis & Therapy · doi:10.1007/s40291-021-00537-3 · Cited by 44
Transcriptional alterations in glioma result primarily from DNA methylation–independent mechanismsPreprint
Court, F., Boiteux, E. L., Fogli, A., Müller-Barthélémy, M., Vaurs‐Barrière, C., Chautard, E., Pereira, B., Biau, J., Kémény, J., Khalil, T., et al. (2019) · Genome Research · doi:10.1101/gr.249219.119 · Cited by 49
Janke, R., Iavarone, A. T., & Rine, J. (2017) · eLife · doi:10.7554/elife.22451 · Cited by 40
Asija, S., Chatterjee, A., Yadav, S., Chekuri, G., Karulkar, A., Jaiswal, A. K., Goda, J. S., & Purwar, R. (2022) · International Reviews of Immunology · doi:10.1080/08830185.2022.2101647 · Cited by 42
Verma, A., & Lindroth, A. M. (2025) · Experimental & Molecular Medicine · doi:10.1038/s12276-025-01537-7 · Cited by 47
Mutations in CIC and IDH1 cooperatively regulate 2-hydroxyglutarate levels and cell clonogenicity
Chittaranjan, S., Chan, S. Y., Yang, C. P., Yang, K., Chen, V., Moradian, A., Firme, M. R., Song, J., Go, N. E., Blough, M. D., et al. (2014) · Oncotarget · doi:10.18632/oncotarget.2401 · Cited by 44
Leibetseder, A., Ackerl, M., Flechl, B., Wöehrer, A., Widhalm, G., Dieckmann, K., Spiegl‐Kreinecker, S., Pichler, J., Hainfellner, J. A., Preusser, M., et al. (2012) · Neuro-Oncology · doi:10.1093/neuonc/nos283 · Cited by 40
Rice, T., Zheng, S. Y., Decker, P. A., Walsh, K. M., Bracci, P. M., Xiao, Y., Mccoy, L. S., Smirnov, I., Patoka, J. S., Hansen, H. M., et al. (2013) · Neuro-Oncology · doi:10.1093/neuonc/nos324 · Cited by 40
TET proteins in cancer: Current ‘state of the art’
Rawłuszko-Wieczorek, A. A., Siera, A., & Jagodziński, P. P. (2015) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2015.07.008 · Cited by 40
McInnes, T., Zou, D., Rao, D. S., Munro, F. M., Phillips, V., McCall, J. L., Black, M. A., Reeve, A. E., & Guilford, P. (2017) · BMC Cancer · doi:10.1186/s12885-017-3226-4 · Cited by 41
Liu, W., Chan, S., Chang, H., Li, G., Tu, Y.-T., Tseng, H., Fu, T., Chang, H.-Y., Liou, H., Ger, L., et al. (2018) · Breast Cancer Research · doi:10.1186/s13058-018-0953-7 · Cited by 40
Incorporating Advances in Molecular Pathology Into Brain Tumor Diagnostics
Vega, J. E. V., & Brat, D. J. (2018) · Advances in Anatomic Pathology · doi:10.1097/pap.0000000000000186 · Cited by 40
Molecular Pathogenesis of Low-Grade Glioma
Bready, D., & Placantonakis, D. G. (2018) · Neurosurgery Clinics of North America · doi:10.1016/j.nec.2018.08.011 · Cited by 40
DNA demethylation is associated with malignant progression of lower-grade gliomas
Nomura, M., Saito, K., Aihara, K., Nagae, G., Yamamoto, S., Tatsuno, K., Ueda, H., Fukuda, S., Umeda, T., Tanaka, S., et al. (2019) · Scientific Reports · doi:10.1038/s41598-019-38510-0 · Cited by 40
Metadata
- Authors
- Turcan, S., Rohle, D., Goenka, A., Walsh, L. A., Fang, F., Yilmaz, E., Campos, C., Fabius, A. W. M., Lu, C., Ward, P. S., Thompson, C. B., Kaufman, A., Guryanova, O., Levine, R., Heguy, A., Viale, A., Morris, L. G. T., Huse, J. T., Mellinghoff, I. K., & Chan, T. A.
- Affiliations
- Memorial Sloan Kettering Cancer Center (US)
- Corresponding author
- Mellinghoff, Ingo K.
- Chan, Timothy A.
- ORCID
- Venue
- Nature
- Published
- 2012-02-15
- Volume
- 483
- Issue
- 7390
- Pages
- 479-483
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- PMC
- PMC3351699
- OpenAlex
- W1988756388
- Cited by
- 1,974
- References
- 44
- Citations by year
- 2026: 90 · 2025: 92 · 2024: 104 · 2023: 100 · 2022: 136 · 2021: 148 · 2020: 140 · 2019: 142 · 2018: 169 · 2017: 144 · 2016: 163 · 2015: 154 · 2014: 153 · 2013: 152 · 2012: 83
- FWCI
- 82.33
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- Funders
- National Cancer Institute (F31CA260794, R01CA154767, U54CA143798, P30CA008748)
- Topics
- Health Sciences › Medicine › Oncology › Glioma Diagnosis and Treatment
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Epigenetics and DNA Methylation
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Chromatin Remodeling and Cancer
- Keywords
- IDH1 mutation, glioma, CpG island methylator phenotype, DNA hypermethylation, 2-hydroxyglutarate, oncometabolites, histone demethylation, methylome, astrocytes, gliomagenesis, hypoxia-inducible factor, epigenetic reprogramming
- MeSH terms
- Astrocytes, Cell Survival, Cells, Cultured, Gene Expression Regulation, Glioblastoma, Glioma, Histones, Humans, Isocitrate Dehydrogenase, Mutation, Phenotype, Tumor Cells, Cultured, CpG Islands, DNA Methylation, Epigenesis, Genetic, Metabolome, HEK293 Cells, Epigenomics
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
